USANA Health Sciences, Inc. — FY2017 Form 10-K
Period clarification: The request identifies 2016 Q4, but the supplied filing is the Form 10-K for the fiscal year ended December 30, 2017. Fiscal 2017 and 2016 were each 52-week years. The filing also reports the fourth quarter of 2017.
Business context
USANA develops and manufactures nutrition, personal care, and wellness products sold through direct selling in 20 markets. It reported approximately 565,000 active Customers at year-end; about 88.4% of FY2017 sales were outside the United States. Asia Pacific generated 77.4% of sales, with Greater China the largest sub-region. Associates accounted for 60% of product sales; Auto Order represented 56% of product sales volume.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net sales | $1,047.3 million | $1,006.1 million |
| Gross profit / margin | $867.9 million / 82.9% | $825.9 million / 82.1% |
| Operating earnings / margin | $132.5 million / 12.7% | $138.6 million / 13.8% |
| Net earnings | $62.5 million | $100.0 million |
| Diluted EPS | $2.53 | $3.99 |
| Operating cash flow | $123.8 million | $137.0 million |
| Cash and cash equivalents at year-end | $247.1 million | $175.8 million |
| Working capital at year-end | $199.0 million | $139.4 million |
Sales rose 4.1%; management attributed the increase principally to Asia Pacific volume growth. Currency movements reduced reported sales by an estimated $6.3 million. Gross margin improved 80 basis points, while SG&A increased to 25.3% of sales from 23.3%, contributing to lower operating earnings. The company reported no outstanding debt at year-end and no balance on its $75 million credit line. FY2017 capital expenditures were $13.2 million; operating cash flow less these expenditures was approximately $110.6 million.
Material changes and unusual items
- Net earnings fell 37.5%, primarily reflecting a $30.1 million one-time, non-cash tax-reform charge and $7.6 million of after-tax costs associated with China and the internal investigation.
- The reported effective tax rate was 53.6%, versus 27.8% in 2016; management stated it would have been 31.2% before U.S. tax-reform adjustments.
- FY2017 included a $2.7 million impairment charge on a secured note receivable from a former nutrition-bar supplier; the company discontinued the supplier relationship and said recoverability would be reassessed.
- China sales were $483.0 million, up from $437.4 million. Americas and Europe sales declined to $236.8 million from $251.6 million; U.S. sales fell 7.2% to $121.1 million.
- Year-end cash increased by $71.4 million. The company repurchased 865,000 shares for $50.0 million during 2017; $50.0 million remained authorized. It has not paid cash dividends.
- China Preferred Customers were reclassified from Associates beginning in Q4 2017, with historical customer counts adjusted for comparison. This affects category comparisons, not the stated total active-customer measure.
Outlook, risks, and contingencies
- Management planned a staged 2018 launch of Celavive skincare in additional markets and targeted increasing skincare from approximately 6% to an estimated 10% of sales by fiscal year-end. The Sensé line was to be phased out. Four European markets—Romania, Germany, Italy, and Spain—were planned to open beginning mid-2018.
- The filing refers to FY2018 net-sales and EPS guidance, but the supplied filing text does not provide clear numerical guidance values. It anticipates higher SG&A and capital spending for technology, infrastructure, product development, and expansion.
- The company is conducting a voluntary internal investigation of BabyCare’s China operations concerning FCPA compliance and expense-reimbursement practices, and has contacted the SEC and DOJ. The duration and outcome are uncertain; additional government action, penalties, legal costs, or business disruption are possible.
- A purported shareholder class action related to the China matters was pending, with a motion-to-dismiss hearing scheduled for March 21, 2018. The company said it intended to defend the action. China regulatory scrutiny, direct-selling license approvals, and restrictions on remitting China profits remain significant risks.
- Other key risks include foreign-exchange exposure, customer and Associate retention, direct-selling regulation, product and advertising compliance, supplier quality and continuity, and cybersecurity. Management reported that the 2016 internal-control material weakness had been remediated; management and KPMG concluded controls were effective as of December 30, 2017.
Important facts for investors to verify
- Confirm FY2018 sales and EPS guidance from the relevant filing disclosures; numerical guidance is not clear in the supplied text.
- Track the China investigation, SEC/DOJ developments, shareholder litigation, related costs, and any resulting operational or financial effects.
- Assess whether sales growth and customer retention can improve in the U.S. and Americas and Europe while China remains a large share of revenue.
- Review the tax-reform charge, future effective tax rate, deferred-tax asset valuation allowances, and withholding-tax assumptions.
- Monitor collection of the impaired supplier note, Celavive’s rollout and sales contribution, and cash availability given that most year-end cash was held by international subsidiaries.